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Diet is a major factor in maintaining a healthy human gastrointestinal tract, and this has triggered the
development of functional foods containing a probiotic and/or prebiotic component intended to improve the
host’s health via modulation of the intestinal microbiota. In this study, a long-term placebo-controlled
crossover feeding study in which each subject received several treatments was performed to monitor the effect
of a prebiotic substrate (i.e., lactulose), a probiotic organism (i.e., Saccharomyces boulardii), and their synbiotic
combination on the fecal microbiota of three groups of 10 healthy human subjects differing in prebiotic dose
and/or intake of placebo versus synbiotic. For this purpose, denaturing gradient gel electrophoresis (DGGE)
analysis of 16S rRNA gene amplicons was used to detect possible changes in the overall bacterial composition
using the universal V3 primer and to detect possible changes at the subpopulation level using group-specific
primers targeting the Bacteroides fragilis subgroup, the genus Bifidobacterium, the Clostridium lituseburense
group (cluster XI), and the Clostridium coccoides-Eubacterium rectale group (cluster XIVa). Although these
populations remained fairly stable based on DGGE profiling, one pronounced change was observed in the
universal fingerprint profiles after lactulose ingestion. Band position analysis and band sequencing revealed
that a band appearing or intensifying following lactulose administration could be assigned to the species
Bifidobacterium adolescentis. Subsequent analysis with real-time PCR (RT-PCR) indicated a statistically sig-
nificant increase (P < 0.05) in total bifidobacteria in one of the three subject groups after lactulose admin-
istration, whereas a similar but nonsignificant trend was observed in the other two groups. Combined RT-PCR
results from two subject groups indicated a borderline significant increase (P  0.074) of B. adolescentis
following lactulose intake. The probiotic yeast S. boulardii did not display any detectable universal changes in
the DGGE profiles, nor did it influence the bifidobacterial levels. This study highlighted the capacity of an
integrated approach consisting of DGGE analysis and RT-PCR to monitor and quantify pronounced changes
in the fecal microbiota of healthy subjects upon functional food administration.
The human gastrointestinal (GI) tract harbors a complex
community of microorganisms, with the largest concentration
of bacteria and metabolic activity being found in the large
intestine (2, 14, 32). According to current insights, the bacterial
groups predominating the large bowel of human adults are
facultative and obligate anaerobes mainly belonging to the
genera Bacteroides, Eubacterium, Clostridium, Ruminococcus,
Bifidobacterium, and Fusobacterium (23). Essentially, the role
of these colonic organisms is confined to the fermentation of
various substrates that escaped digestion in the upper GI tract.
Whereas saccharolytic fermentation of carbohydrates leads to
the production of short-chain fatty acids that provide addi-
tional energy to the host, the end products of proteolytic (pro-
tein) fermentation include various toxic substances such as
phenolic compounds, amines, and ammonia. Colon bacteria
are often classified as potentially harmful or potentially health
promoting based on their fermentative features. In any given
situation of intestinal balance, increased numbers of proteo-
lytic clostridia and Bacteroides can be detrimental to health
(11), while stimulation of bifidobacteria and lactobacilli is gen-
erally regarded as beneficial (10). The range of positive effects
that have been linked to bifidobacteria and lactobacilli include
stimulation of the immune system, production of vitamins,
inhibition of intestinal pathogens, reduction of blood ammonia
and cholesterol levels, and reduction of constipation (12, 33).
The fact that diet is a major factor controlling intestinal
balance has triggered the development of so-called functional
foods containing a probiotic and/or prebiotic component.
Probiotics are commonly referred to as live microorganisms
(bacteria or yeasts), which, when administered in adequate
amounts, confer a health benefit on the host (8). However,
other studies have suggested that inactivated microbes and
their components can also exert probiotic effects (17, 43). Bac-
terial probiotic strains that are incorporated into commercial
products worldwide most frequently belong to the genera Bi-
fidobacterium and Lactobacillus. A prebiotic is a nondigestible,
selectively fermented compound that induces specific changes
in the composition and/or activity of the gastrointestinal mi-
crobiota that are beneficial for a host’s well-being and health
(13). Several oligosaccharides have been studied as potential
prebiotics, including lactulose, galactooligosaccharides, fruc-
tooligosaccharides (oligofructose and inulin), and soybean oli-
gosaccharides (6). Essentially, the aims of pro- and prebiotic
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supplementation are highly similar (i.e., to improve the host’s
health via modulation of the intestinal microbiota) but are
achieved in different ways, namely, by introducing exogenous
species (probiotics) or by stimulating indigenous bacteria (pre-
biotics), respectively.
The inadequacy of conventional culture techniques to reflect
the microbial diversity of the intestinal ecosystem (20, 22, 35)
has triggered the development of culture-independent tech-
niques for the evaluation of pro- and prebiotic administration
in humans. Commonly used molecular approaches to analyze
the intestinal microbiota upon dietary intervention include
population fingerprinting techniques like denaturing gradient
gel electrophoresis (DGGE) or temperature gradient gel elec-
trophoresis (34, 38) and terminal restriction fragment length
polymorphism (19). These PCR-based tools allow the visual-
ization of the predominant genetic diversity without prior
knowledge of the composition or complexity of the microbial
ecosystem present in the sample. Unlike population finger-
printing methods, fluorescent in situ hybridization (16, 42) and
real-time PCR (RT-PCR) (15, 24) are able to generate more
quantitative information for specific fecal bacterial groups. Al-
though each of these techniques has been applied to human
feeding trials, to our knowledge, no study so far has reported
the integrated use of DGGE and RT-PCR to monitor the
effects of pro-, pre-, and synbiotics on the fecal microbiota of
healthy humans.
To demonstrate the efficacy of functional food components
under in vivo conditions and to substantiate claims from stud-
ies in vitro and using experimental models, well-designed hu-
man dietary intervention studies are required (45). In the cur-
rent study, a long-term placebo-controlled crossover feeding
study was set up to monitor the effect of a prebiotic substrate
(i.e., lactulose), a probiotic organism (i.e., Saccharomyces bou-
lardii), and the synbiotic combination of the two on the pre-
dominant bacterial population of 30 healthy human subjects.
Lactulose is a commercially available disaccharide that is used
as a drug in the treatment of hepatic encephalopathy and
chronic constipation (46), which has been shown to stimulate
the growth of bifidobacteria (41). The probiotic yeast Saccha-
romyces boulardii is a biotherapeutic agent available as a reg-
istered pharmaceutical product and is used in the prevention
and treatment of various types of diarrhea (9, 18, 36). For this
purpose, modifications in the overall bacterial composition of
fecal samples were monitored by population fingerprinting us-
ing DGGE analysis of 16S rRNA gene amplicons. In this way,
DGGE analysis allowed the detection of pronounced changes
in the predominant fecal microbiota following pro-, pre-, or
synbiotic administration using the universal 16S rRNA gene V3
primer but also allowed the detection of changes at subpopu-
lation level using group-specific primers targeting the Bacte-
roides fragilis subgroup, the genus Bifidobacterium, the Clos-
tridium lituseburense group (cluster XI), and the Clostridium
coccoides-Eubacterium rectale group (cluster XIVa). Pronounced
changes revealed by DGGE analysis were further characterized
by RT-PCR in order to obtain a quantitative estimate of the
dietary intervention effect in healthy humans.
MATERIALS AND METHODS
Subjects. Thirty healthy volunteers (11 women and 19 men) aged 23  2 years
(range, 20 to 26 years) participated in the study. None of the subjects had a
history of gastrointestinal or metabolic disease or previous surgery (apart from
appendectomy). The subjects did not receive antibiotic treatment or any other
medical treatment influencing intestinal microbiota during the 3 months before
the start of the study. Subjects were advised to maintain their usual diet during
the study period and to avoid the intake of fermented milk products and food
components containing high quantities of fermentable carbohydrates. The Ethics
Committee of the University of Leuven (Belgium) approved the study, and all
subjects gave informed consent.
Experimental design and sample collection. Healthy volunteers were ran-
domly assigned to three different treatment groups of a placebo-controlled cross-
over trial in which each subject participated in several treatments. The study was
conducted over an 18-week period, which was divided into three ingestion peri-
ods of 4 weeks followed by a 4-week washout period, each separated by a 3-day
sample collection interlude: (i) prebiotic period (day 1 to day 28), (ii) double
placebo/synbiotic period (day 32 to day 60), (iii) probiotic period (day 64 to day
92), and (iv) washout period (day 96 to day 120) (Fig. 1). Lactulose (Duphalac;
Solvay Pharma & Cie, Brussels, Belgium) and Saccharomyces boulardii (Enterol;
Biomed, Du¨bendorf, Switzerland) were selected as prebiotic and probiotic com-
pounds, respectively. The placebo consisted of maltodextrin (Paselli MD6;
AVEBE B.A. Food, Foxhol, The Netherlands), an oligosaccharide that is ob-
tained by enzymatic conversion of potato starch and that is completely digestible
in the human small intestine. Twice a day, group 1 received 10 g lactulose
together with 250 mg S. boulardii placebo in the first ingestion period (prebiotic),
10 g lactulose together with 250 mg S. boulardii placebo in the second ingestion
period (placebo), 10 g lactulose placebo together with 250 mg S. boulardii in the
third ingestion period (probiotic), and no intake during the final period (wash-
out). According to the manufacturer, 250 mg of S. boulardii contains at least
2.5  109 viable lyophilized cells at the date of fabrication and 109 cells at the
expiration date. However, the exact number of viable lyophilized cells at the
moment of intake is unknown. Group 2 followed the same design except that
higher doses of both active product and the respective placebo were adminis-
tered: 15 g of lactulose and 500 mg of S. boulardii. Group 3 was analogous to
group 1 except that the double-placebo period was replaced by the synbiotic
combination of 10 g lactulose and 250 mg S. boulardii. The doses administered
were chosen based on therapeutic recommendations in a way that subjects did
not suffer from negative effects or discomfort. Throughout the study, the volun-
FIG. 1. Schematic representation of the study design. The arrows (S1 to S5) indicate the time points of stool sample collection.
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teers consumed their usual diet, taking care that the diet remained as stable as
possible over the four periods. In addition, they were advised to avoid the intake
of fermented milk products and food components containing high quantities of
fermentable carbohydrates.
Before the start of the feeding study, at the end of each ingestion period, and
at the end of the washout period, all stool samples produced during 72 h were
collected. Because the mean transit takes between 60 and 72 h, samples were
collected during three consecutive days. Each sample collected during 72 h was
analyzed separately. Upon the collection of the fecal samples, 5 g (wet weight)
was immediately frozen at 20°C for the purpose of DNA extraction.
Processing and total DNA extraction of the fecal samples. Processing of the
fecal samples and subsequent bacterial DNA extraction using a modified version
of the method of Pitcher and coworkers (29) was performed as previously
described (44).
Primer design and PCR program for DGGE. Based on 16S rRNA gene
sequences available from the EMBL database (http://srs6.ebi.ac.uk), specific
PCR-DGGE primers for the Bacteroides fragilis subgroup and Clostridium clus-
ters XI and XIVa were designed using Kodon (version 1.0) software (Applied
Maths, St.-Martens-Latem, Belgium) as previously described (44) (Table 1).
Validation of the developed primers was first performed in silico followed by in
vitro specificity tests using type strains of species autochthonous to the human
intestinal tract (Table 2). Other 16S rRNA gene primers used in this study
targeting all (predominant) bacteria and the genus Bifidobacterium are listed in
Table 1. The forward or reverse primer of each primer set was extended with a
GC clamp at the 5 end to allow the detection of all amplicons with DGGE.
PCR assays were performed as previously described (44), using a single PCR
core program for all primer pairs with primer-specific annealing temperatures
(Table 1).
DGGE analysis and processing of the gels. 16S rRNA gene amplicons were
analyzed with DGGE as previously described (44). In this study, different types
of denaturing gradients were applied, depending on the primers used (Table 1).
DGGE gels were stained for 30 min with 1 SYBR gold (catalog no. S-11494;
Molecular Probes) in 1 TAE buffer (catalog no. 161–0773; Bio-Rad).
Inclusion of a standard reference every six lanes in each DGGE gel allowed
the normalization of gel profiles using BioNumerics (BN) software, version 4.00
(Applied Maths, St.-Martens-Latem, Belgium). This normalization step enabled
a comparison between DGGE profiles from different gels, provided that these
gels were run under comparable denaturing and electrophoretic conditions.
Cluster analysis of DGGE pattern profiles was performed using the unweighted-
pair group method using arithmetic averages hierarchical clustering algorithm,
and similarity between profiles was expressed by the curve-based Pearson prod-
uct-moment correlation coefficient.
To perform band position analysis, a database containing the V3 primer am-
plicon DGGE band positions of all human GI tract-associated Bifidobacterium
species was constructed using BN software. By comparing the V3 band position
in the sample profiles with the BN database, a first tentative identification was
obtained.
RT-PCR analysis. Quantification of total bifidobacteria and Bifidobacterium
adolescentis was performed with the LightCycler System I (Roche, Mannheim,
Germany) using the FastStart DNA Master SYBR Green I kit and specific PCR
primers (Table 1). To determine total bifidobacteria numbers present in the
samples, g-Bifid primers (23) without a GC clamp were used. To determine the
relative concentration of B. adolescentis, primers F_ado_IS and R_ado_IS tar-
geting the intergenic spacer region of the 16S-23S rRNA gene described previ-
ously by Haarman and Knol (15) were used. The specificity of this primer set was
confirmed against a panel of reference strains representing all human GI tract-
associated Bifidobacterium species (Table 2) and Bifidobacterium ruminantium.
The efficiency of RT-PCR amplification was optimized for both primer sets.
The highest efficiencies were obtained using 4 mM (final concentration) MgCl2
TABLE 1. Specifications of the 16S rRNA gene primers used in this study
Target group Primer Primer sequencea (5–3) Ampliconsize (bp)
Annealing
temp (°C)
Analysis used
(gradient range %)
Reference
or source
All bacteria F357-GC GC clamp-TACGGGAGGCAGCAG 234 55 DGGE (35–70) 27
R518 ATTACCGCGGCTGCTGG
Bacteroides fragilis Bfra 531F ATACGGAGGATCCGAGCGTTA 293 65 DGGE (35–60) This study
subgroup Bfra 766R-GC GC clamp-CTGTTTGATACCCACACT
Bifidobacterium g-Bifid F CTCCTGGAAACGGGTGG 596 65 DGGE (40–70) 23
g-Bifid R-GC GC clamp-GGTGTTCTTCCCGATATCTACA
Clostridium clusters Erec 688F GCGTAGATATTAGGAGGAAC 211 60 DGGE (35–70) This study
XI and XIVa Erec 841R-GC GC clamp-TGCGTTWGCKRCGGCACCG
Bifidobacterium F_ado_IS ATAGTGGACGCGAGCAAGAGA 71 65 RT-PCR 15
adolescentis R_ado_IS TTGAAGAGTTTGGCGAAATCG
a The GC clamp sequence is as follows: CGCCCGCCGCGCCCCGCGCCCGGCCCGCCGCCCCCGCCCC.
TABLE 2. Results of 16S rRNA gene primer specificity tests
Species Strain
Amplicon obtained with primer a:
V3 Bfra g-Bifid Erec Ado_IS
Bacillus cereus LMG 6923T     
Bacteroides distansonius DSM 20701T     
Bacteroides fragilis subgroupb     
Bifidobacterium speciesc     g
Clostridium clusters I and IId     
Clostridium cluster XIe     
Clostridium cluster XIVf     
Enterobacter aerogenes LMG 2094T     
Enterococcus solitarius LMG 12890T     
Escherichia coli LMG 2092T     
Faecalibacterium prausnitzii A2-16S     
Lactobacillus salivarius LMG 9477T     
Pediococcus pentosaceus LMG 11488T     
Prevotella melaninogenica DSM 7089T     
Proteus mirabilis LMG 3257T     
Staphylococcus aureus LMG 8064T     
Streptococcus salivarius LMG 11489T     
Veillonella parvula DSM 2008T     
a , positive; , negative.
b The Bacteroides fragilis subgroup strains tested were Bacteroides fragilis LMG
10263T, Bacteroides eggerthii DSM 20697T, Bacteroides ovatus DSM 1896T, Bac-
teroides thetaiotaomicron DSM 2079T, and Bacteroides vulgatus LMG 17767T.
c Bifidobacterium strains tested were B. adolescentis LMG 10502T, B. angula-
tum LMG 10503T, B. bifidum LMG 11041T, B. breve LMG 11042T, B. catenula-
tum LMG 11043T, B. dentium LMG 11045T, B. gallicum LMG 11596T, B. infantis
LMG 8811T, B. longum LMG 13197T, B. pseudocatenulatum LMG 10505T, and
B. ruminantium LMG 12588T.
d Clostridium cluster I and II strains tested were C. beijerinckii LMG 5716T, C.
butyricum LMG 1217T, C. perfringens LMG 11264T, C. sporogenes LMG 8421T,
and C. tyrobutyricum LMG 1285T.
e Clostridium cluster XI strains tested were C. bifermentans LMG 3029T, C.
sordellii LMG 15708T, and Peptostreptococcus anaerobius LMG 15865T.
f Clostridium cluster XIV strains tested were Anaerostipes caccae DSM 14662T,
C. nexile DSM 1787T, Eubacterium hallii L2-7, Eubacterium rectale ATCC
33656T, Roseburia intestinalis DSM 14610T, and Ruminococcus productus LMG
21654T.
g Positive for Bifidobacterium adolescentis only.
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at an annealing temperature of 65°C for both primer sets. The 20-l reaction
mixture contained 4 mM MgCl2, 2 l of 10 Mastermix (including FastStart
enzyme, FastStart Taq DNA polymerase, reaction buffer, deoxynucleoside
triphosphate mixture, MgCl2, and SYBR Green I dye), 2 l of template DNA,
and 1 mM of each primer. The temperature program for RT-PCR included one
cycle at 95°C for 10 min for initial denaturation and activation of the FastStart
Taq DNA polymerase followed by 40 cycles of denaturation at 95°C for 0 s
followed by annealing at 65°C for 5 s and elongation at 72°C for 23 s and 5 s for
g-Bifid and ado_IS primers, respectively. Detection of the fluorescent product
was set at the end of the elongation step at each cycle. The melting curve was
obtained by slow heating with a 0.1°C/s increment from 75°C to 95°C with
continuous fluorescence measurement. Melting-point-determination analysis al-
lowed the confirmation of the specificity of the amplification products. Calibra-
tion curves were constructed using dilutions of genomic DNA from a control
strain (B. adolescentis LMG 10502) for which the number of bifidobacteria was
determined by plate counting on MRS agar (Difco) incubated at 37°C under
anaerobic conditions. The data presented are the mean values of duplicate
RT-PCR analyses of the same DNA extracts in two independent runs.
Statistical analysis. Results are expressed as mean values and standard devi-
ations. Statistical analysis was performed with SPSS software (SPSS 12.0 for
Windows; SPSS Inc., Chicago, IL). Given the low number of subjects in the
treatment groups, nonparametric statistical analysis was used regardless of the
distribution of results (Friedman analysis of variance [ANOVA]). The level for
statistical significance was set at a P value of 	0.05.
RESULTS
Population profiling with DGGE. PCR-DGGE analysis with
universal primers targeting the V3 region of the 16S rRNA
gene was used to analyze the stability of the predominant fecal
bacterial population of the samples across the different sam-
pling periods (Fig. 2). Samples from all sampling points were
pooled per person and analyzed on the same DGGE gel to rule
out the possible influence of variations in electrophoretic con-
ditions between different gels. Population fingerprint profiles
were compared and analyzed both visually and numerically.
Overall, DGGE band profiles of V3 16S rRNA gene ampli-
cons displayed a relatively high complexity (mean of 20.4 bands
per profile) and were relatively stable for each subject (Fig. 2).
Between different subjects, considerable variation in the com-
position of the population fingerprints could be observed (data
not shown). Although profiles were relatively stable for each
subject, small qualitative (the presence or absence of a band)
or quantitative (variable intensity of a band) variations did
occur (even between two samples from the same day), most of
which were subject specific (Fig. 2). However, one band frag-
ment at a specific position in the V3 profiles appeared (n 
 5)
or intensified (n 
 17) after lactulose ingestion in 22 of the 30
subjects. In five other subjects, the band was already present
and remained equally intense (Fig. 2). In the three remaining
subjects, the band was absent during the entire study. Re-
peated PCR-DGGE analyses of the same DNA extracts con-
firmed this observation (data not shown). This particular band
was located in the high-percentage denaturant zone of the
DGGE gel, indicating that it most probably represented a
member of the genus Bifidobacterium, given the high percent-
age of GC genome content of these organisms (55 to 67
mol%). After comparing the V3 band positions of all known
Bifidobacterium species, only two species matched the partic-
ular band position, namely, B. adolescentis and B. ruminantium
(Fig. 3). In contrast, the intake of placebo or S. boulardii with
or without lactulose did not result in any uniform change in the
DGGE band profiles (Fig. 2).
In addition to universal primers, a set of group-specific prim-
ers was applied to analyze the stability of certain fecal sub-
populations during the intake periods. The Bacteroides fragilis
(Fig. 4a) and Bifidobacterium (Fig. 4b) subpopulation, visual-
ized by primers Bfra and g-Bifid, showed fairly stable profiles
within each individual over the complete study period in all
three test groups. These profiles were less complex than the
profiles generated with the universal V3 primer and displayed
FIG. 2. V3 16S rRNA gene DGGE profiles from all five sampling
points (S1 to S5) of three individual subjects (I1 to I3), each repre-
senting one of the three test groups (G1 to G3). The day of sample
collection at a given sampling point is indicated (day 1 [d1], d2, and
d3). The square contains the band that appeared or intensified after
lactulose intake (S2). There were three different scenarios regarding
the presence of this band after lactulose ingestion: intensification (I1),
appearance (I2), or remaining equally intense (I3).
FIG. 3. Comparison of V3 16S rRNA gene primer DGGE profile
(50% to 70% gradient) of sample I2 G2 S2 d1 (see Fig. 2 legend) with
the DGGE band positions of type and reference strains of Bifidobac-
terium species associated with the human GI tract and of B. ruminan-
tium. The square contains the band that appeared or intensified after
lactulose intake.
VOL. 72, 2006 PRE- AND PROBIOTIC EFFECTS ON FECAL MICROBIOTA 5993
less subject-specific variations. Based on band position analy-
sis, profiles permitted the assignment of specific bands to
known colonic species (Fig. 4a and b). In contrast, the com-
plexity of the profiles of Clostridium clusters XI and XIVa (Fig.
4c), obtained with the Erec primer set, were comparable to the
profiles obtained with the universal V3 primer. The profiles
remained largely unchanged during the entire test period in all
three test groups. Because a larger subgroup is targeted by this
primer set, it was not possible to link band positions to specific
species.
DGGE band sequence analysis. The DGGE band fragment
that appeared or intensified after lactulose ingestion was fur-
ther characterized by sequencing analysis in order to link it to
a specific Bifidobacterium species. This particular band was
extracted from the V3 profiles of nine subjects from the three
test groups and yielded identical 150-bp sequences in all these
samples (data not shown). After comparison with the EMBL
database, the sequence of the band in question exhibited the
highest similarity (100%) with the 16S rRNA gene sequence of
B. adolescentis and B. ruminantium followed by B. thermacido-
phylum, B. boum, B. catenulatum, and B. pseudocatenulatum,
with a sequence similarity of 96.7%. Given the fact that B.
ruminantium has never been reported to occur in humans and
because of the documented predominance of B. adolescentis in
the human gut, the band fragment was assigned to the latter
species.
Quantification of fecal bifidobacteria using real-time PCR.
Since the Bifidobacterium population and particularly the spe-
cies Bifidobacterium adolescentis appeared to be influenced by
lactulose administration, real-time PCR was used to quantify
the total fecal bifidobacteria (Table 3) and B. adolescentis
(Table 4).
A statistically significant increase (P	 0.05) in the total level
of fecal bifidobacteria was observed in group 3 after the intake
of lactulose compared to the baseline conditions and synbiotic
intake (Table 3). In groups 1 and 2, a nonsignificant tendency
towards higher Bifidobacterium levels following lactulose in-
take was observed. A combination of the results of groups 1
and 3 (both of which received the same dose of lactulose
during the first intake period) before and after lactulose intake
resulted in a significant increase in the levels of fecal bifidobac-
teria, from 8.14  1.09 to 8.99  0.60 log10 bifidobacteria/g
(wet weight) (P 
 0.021). A mean standard deviation of 0.18
log10 bifidobacteria/g was obtained from duplicate RT-PCR
runs, which is indicative of the good reproducibility of the
method.
Nonsignificant tendencies indicating higher relative num-
bers after lactulose administration could be observed in the
RT-PCR-based quantification of B. adolescentis (Table 4). A
combination of the results from groups 1 and 3 before and
after lactulose intake resulted in a borderline significant in-
crease of the fecal B. adolescentis levels from 7.42  1.09 to
7.84  1.06 log10 bifidobacteria/g (wet weight) (P 
 0.074).
These results support the assumption that the DGGE band
being discussed indeed represents a B. adolescentis species and
not B. ruminantium, as the ado_IS primer set was shown to be
specific for B. adolescentis in RT-PCR analyses (data not
shown).
Although all subjects showed an overall increase in total
levels of bifidobacteria and B. adolescentis after lactulose in-
gestion, these changes did not have the same proportional
effect in all subjects. For instance, it was found that in one of
the subjects, the DGGE band representing B. adolescentis was
not present in the baseline sample but appeared as a very
FIG. 4. Clustering of group-specific DGGE band profiles from
sampling points S1 to S5 of a representative subject from group 2: the
Bacteroides fragilis subgroup (a), the genus Bifidobacterium (b), and
Clostridium clusters XI and XIVa (c). By comparison to a DGGE
database, band position analysis allowed the assignment of specific
bands to the following species: Bacteroides vulgatus (a1), Bacteroides
ovatus and/or Bacteroides fragilis and/or Bacteroides thetaiotaomicron
(a2), Bacteroides uniformis (a3), B. adolescentis (b1), B. adolescentis
(b2), B. longum/B. infantis (b3), B. breve (b4), and B. adolescentis (b5).
Assignment of bands was not possible for the profiles for Clostridium
clusters XI and XIVa because of the size of this group.
TABLE 3. Results of RT-PCR-based quantification of total bifidobacteria in the three different treatment groups a
Group
Total bifidobacteria (log10 bifidobacteria/g wet wt)
P value
Baseline (S1) Lactulose (S2) Placebo/synbiotic (S3) S. boulardii (S4) Washout (S5)
1 8.57  0.67 8.95  0.81 8.23  0.73 8.20  0.62 8.40  0.78 0.371 (NS)
2 8.61  0.82 9.31  0.72 8.53  0.80 8.60  1.08 8.62  0.50 0.120 (NS)
3 7.79  1.27 8.98  0.40b 8.38  0.50 8.13  1.35 8.43  1.41 	0.05
a  
 0.05 (Friedman ANOVA). S1, first time point of stool sample collection; NS, not significant.
b Significantly different from baseline (P
 0.007) and synbiotic (P
 0.004) and borderline significantly different from S. boulardii cells (P
 0.061) and washout (P

0.099).
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intense fragment after lactulose ingestion. In RT-PCR, this
change was accompanied by a relative increase from 7.11 log10
to 9.26 log10 for the total bifidobacteria and from 5.41 log10 to
8.23 log10 for B. adolescentis. Likewise, two subjects for which
no B. adolescentis cells could be detected in their fecal samples
using RT-PCR lacked the DGGE band at the B. adolescentis
position. A more detailed analysis of the RT-PCR data showed
that the proportional increase in levels of total bifidobacteria
and B. adolescentis was correlated to some extent with the
initial level of bifidobacteria present (data not shown). Overall,
subjects with lower initial bifidobacterial counts showed higher
rates of response to lactulose administration than those exhib-
iting higher numbers under baseline conditions. No dose-effect
relation was found for lactulose or S. boulardii.
DISCUSSION
In various studies that have analyzed the effect of pre-, pro-,
and synbiotics on the human intestinal microbiota, it has been
shown that bifidobacteria and lactobacilli can be stimulated,
leading to a relative decrease of other organisms such as clos-
tridia, streptococci, Bacteroides, and coliforms. Many of those
studies still relied on conventional culture techniques (5, 21),
which are less suitable for microbial monitoring and studying
population dynamics than culture-independent approaches. In
this study, the qualitative composition of the fecal microbiota
was analyzed during the intake of a prebiotic and/or probiotic
compound by DGGE using universal and group-specific prim-
ers. Subsequently, profound changes in DGGE patterns linked
to prebiotic intake were further characterized quantitatively
using two RT-PCR assays targeting total bifidobacteria and B.
adolescentis. DGGE profiles of the predominant fecal micro-
biota using universal V3 16S rRNA gene primers generated
complex but overall relatively stable and unique profiles in
each of the three test groups. This confirms previous findings
demonstrating the subject specificity of the predominant fecal
microbiota in humans and its stability over a prolonged period
of time (44, 47). Occasionally, subject-specific variations did
occur during the intake period, most of which are probably due
to variations in the daily diet of the subjects. One specific V3
DGGE band fragment that was observed in 90% of the sub-
jects following lactulose intake was selected for further char-
acterization. Based on the relative position of the band and
sequence analysis of the extracted V3 amplicon, the band could
be assigned to the species B. adolescentis and/or B. ruminan-
tium. Because the two species display high 16S rRNA gene
sequence similarities (up to 98.9%), reliable discrimination
between both taxa was not possible. B. ruminantium is a typical
rumen bacterium (3) that has so far never been reported in the
human GI tract. Taken together with the fact that B. adoles-
centis is considered to be one of the most dominant Bifido-
bacterium species in the intestinal tract of human adults (24,
37), it can be concluded that the particular V3 band fragment
represents B. adolescentis rather than B. ruminantium.
Because DGGE can, at its best, be considered as a semi-
quantitative tool for monitoring bacterial populations, addi-
tional analysis with RT-PCR was required to obtain a quanti-
tative estimation of the stimulation of bifidobacteria following
lactulose intake. In RT-PCR analyses, both the total bifidobac-
teria as well as B. adolescentis counts increased after lactulose
intake independent of the administered dose, but this effect
was found to be statistically significant only for total bifidobac-
teria. This finding may suggest that the increase in total bi-
fidobacteria levels is not only due to the rise in B. adolescentis
and also that other members of the genus Bifidobacterium,
including B. catenulatum, B. pseudocatenulatum, B. longum,
and B. infantis, may be influenced by the administration of
lactulose. Most prebiotic feeding studies in which a bifidogenic
effect was reported analyzed only total bifidobacteria levels.
Tannock and coworkers (38) also demonstrated changes at the
species level through the detection and increased staining in-
tensity of RNA-DGGE bands assigned to B. adolescentis and
Colinsella aerofaciens after the consumption of galactooligo-
saccharide- and fructooligosaccharide-containing biscuits.
The increase in fecal bifidobacteria after lactulose ingestion
has been reported in various studies using culture-based meth-
odologies (1, 3, 31, 39, 40) and fluorescent in situ hybridization
analysis (41). To our knowledge, this is the first human study
using DGGE and RT-PCR in an integrated approach to indi-
cate an in vivo bifidogenic effect of lactulose. The stimulating
effect of lactulose appeared to be restricted to the period of
supplementation, as numbers of bifidobacteria returned to
baseline levels after administration stopped. Also, in other
prebiotic feeding studies (30, 42), increased numbers of fecal
bifidobacteria returned to initial levels once prebiotic ingestion
had ceased. This finding demonstrates the selective nature of
prebiotic fermentation in the colon and supports the concept
of beneficial modulation of the gut microbiota through dietary
supplementation with specific oligosaccharides. Along with
positive effects on the bacterial composition, prebiotic admin-
istration can also exert favorable effects on the intestinal met-
abolic activity, e.g., colonic NH3 metabolism. In this context,
the colonic ammonia-nitrogen metabolism was investigated in
the same volunteers by means of the biomarker lactose-
[15N15N]-ureide and indicated a significant reduction of the
urinary 15N excretion after the intake of lactulose, which was
accompanied by a significant increase in the fecal 15N output,
as was also demonstrated by higher 15N levels found in the
fecal bacterial fractions (7). The observed decrease in levels of
TABLE 4. Results of RT-PCR-based quantification of Bifidobacterium adolescentis in the three different treatment groupsa
Group
B. adolescentis level (log10 B. adolescentis cells/g wet wt)
P value
Baseline (S1) Lactulose (S2) Placebo/synbiotic (S3) S. boulardii (S4) Washout (S5)
1 7.76  1.01 7.97  0.94 7.95  0.32 7.29  1.14 7.41  1.13 0.435 (NS)
2 7.41  1.22 8.14  1.06 7.27  0.98 7.52  1.21 7.41  0.93 0.164 (NS)
3 7.14  1.12 7.75  1.16 7.35  1.01 7.50  0.96 7.68  1.05 0.306 (NS)
a  
 0.05 (Friedman ANOVA). S1, first time point of stool sample collection; NS, not significant.
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bifidobacteria after synbiotic treatment remains unclear. Pos-
sibly, consumption of lactulose by the probiotic yeast S. bou-
lardii (26) and/or spatial competition between S. boulardii and
the Bifidobacterium population may have contributed to this
decrease.
From a methodological point of view, it is interesting that
the intensity of the DGGE band representing B. adolescentis
seemed proportional to the amount of total bifidobacteria and
B. adolescentis determined by RT-PCR. Likewise, Bibiloni and
coworkers (4) showed that an increased band intensity was
correlated with relative abundance based on dot blot hybrid-
ization. In other studies, internal-standard systems were devel-
oped for DGGE analysis to conduct comparisons of relative
fragment staining intensities (28, 38). As initially noticed by
Roberfroid and colleagues (30) and as later confirmed in other
studies (25, 42), the relative increase in levels of fecal bi-
fidobacteria probably depends more on the baseline concen-
tration of Bifidobacterium than on the prebiotic dose adminis-
tered. A similar effect was also observed in the present study
and could suggest that prebiotic intake may be particularly
effective for subjects exhibiting low intrinsic numbers of bi-
fidobacteria. On the other hand, it should be kept in mind that
logarithmic values can give a biased view of absolute increases.
For instance, an apparently small increase of 0.2 log10 starting
from a baseline level of 9.3 log10 is comparable to an increase
of 3.1 log10 starting from an initial concentration of 6.0 log10.
The observation that the administration of the probiotic
yeast S. boulardii did not appear to cause profound changes in
the intestinal microbiota of healthy subjects may not be en-
tirely unexpected. Whereas S. boulardii is specifically used as a
biotherapeutic agent for the prevention and treatment of dif-
ferent types of diarrhea (9, 18, 36), none of the subjects in this
study had a disturbed intestinal balance or suffered from diar-
rhea during the sampling period. The therapeutic effects of S.
boulardii in healthy subjects may be minimal compared to
those in patients suffering from diarrhea.
Group-specific primers were used to allow a more in-depth
analysis of three bacterial subpopulations of the human colon.
However, DGGE profiles of the Bacteroides fragilis subgroup,
the genus Bifidobacterium, and Clostridium clusters XI and
XIVa were relatively stable and did not reveal significant tem-
poral shifts during the feeding trial. These results are consis-
tent with the findings of previous studies in which no major
shifts of predominant autochthonous bacterial groups were
observed (34, 44). In contrast to the observations from univer-
sal profiles, stimulation of B. adolescentis after lactulose inges-
tion could not be detected in the Bifidobacterium profiles,
possibly because of the target concentration effect. It can be
assumed that the use of universal primers will yield a DGGE
band for only the most predominant species representing the
largest fraction of the community DNA. Group-specific prim-
ers are directed to only a fraction of the total DNA pool, in
which case concentration differences are expected to be less
pronounced in the subpopulation DGGE profile.
In conclusion, this study has demonstrated that an inte-
grated use of DGGE and RT-PCR has the potential to mon-
itor the effects of pro-, pre-, and synbiotic intake on the pre-
dominant fecal microbiota of humans. Universal V3 primer
DGGE fingerprint profiles from fecal samples revealed an
effect of lactulose administration on fecal bifidobacteria and in
particular on B. adolescentis. Subsequent quantification with
RT-PCR confirmed the stimulation of total bifidobacteria and
B. adolescentis. Because changes occurring mainly in the dom-
inant bacterial populations can be detected, it cannot be ex-
cluded that subtle changes in less predominant species or
groups of species may remain undetected by this approach.
Although the sensitivity of this strategy needs to be elaborated
further, the combination of DGGE analysis and RT-PCR
quantification may be considered a promising approach in fu-
ture studies, e.g., to analyze disturbed intestinal microbiota of
specific patient groups. Especially in chronic intestinal disor-
ders such as inflammatory bowel disease, in which the intesti-
nal microbiota is believed to play a role in the (aethio)patho-
genesis of the disease, this integrated approach could be useful
to monitor potential indicator organisms and to assess the
effects of new biotherapeutic agents during clinical interven-
tion studies.
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